BIOMAT Database Logo BIOMAT Database Logo

Comparison of saruplase and alteplase in acute myocardial infarction. SESAM Study Group. The Study in Europe with Saruplase and Alteplase in Myocardial Infarction. 1997

F W Bär, and J Meyer, and F Vermeer, and R Michels, and B Charbonnier, and K Haerten, and M Spiecker, and C Macaya, and M Hanssen, and M Heras, and J P Boland, and M C Morice, and F G Dunn, and R Uebis, and C Hamm, and O Ayzenberg, and G Strupp, and A J Withagen, and W Klein, and J Windeler, and G Hopkins, and H Barth, and M J von Fisenne
Department of Cardiology, University Hospital Maastricht, The Netherlands.

Four hundred seventy-three patients with acute myocardial infarction (AMI) were treated with either saruplase (80 mg/hour, n = 236) or alteplase (100 mg every 3 hours, n = 237). Comedication included heparin and acetylsalicylic acid. Angiography was performed at 45 and 60 minutes after the start of thrombolytic therapy. When flow was insufficient, angiography was repeated at 90 minutes. Coronary angioplasty was then performed if Thrombolysis In Myocardial Infarction (TIMI) trial 0 to 1 flow was seen. Control angiography was at 24 to 40 hours. Baseline characteristics were similar. Angiography showed comparable and remarkably high early patency rates (TIMI 2 or 3 flow) in both treatment groups: at 45 minutes, 74.6% versus 68.9% (p = 0.22); and at 60 minutes 79.9% versus 75.3% (p = 0.26). Patency rates at 90 minutes before additional interventions were also comparable (79.9% and 81.4%). Angiographic reocclusion rates were not significantly different: 1.2% versus 2.4% (p = 0.68). After rescue angioplasty, angiographic reocclusion rates of 22.0% and 15.0% were observed. Safety data were similar for both groups. Thus, (1) early patency rates were high for saruplase and alteplase treatment, (2) reocclusion rates for both drugs were remarkably low, and (3) complication rates were similar. Thus, saruplase seems to be as safe and effective as alteplase.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D010959 Tissue Plasminogen Activator A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases. Alteplase,Plasminogen Activator, Tissue-Type,T-Plasminogen Activator,Tissue-Type Plasminogen Activator,Actilyse,Activase,Lysatec rt-PA,TTPA,Tisokinase,Tissue Activator D-44,Lysatec rt PA,Lysatec rtPA,Plasminogen Activator, Tissue,Plasminogen Activator, Tissue Type,T Plasminogen Activator,Tissue Activator D 44,Tissue Type Plasminogen Activator
D010960 Plasminogen Activators A heterogeneous group of proteolytic enzymes that convert PLASMINOGEN to FIBRINOLYSIN. They are concentrated in the lysosomes of most cells and in the vascular endothelium, particularly in the vessels of the microcirculation. Extrinsic Plasminogen Activators,Plasminogen Activator,Uterine-Tissue Plasminogen Activator,Uterine Tissue Plasminogen Activator
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005060 Europe The continent north of AFRICA, west of ASIA and east of the ATLANTIC OCEAN. Northern Europe,Southern Europe,Western Europe
D005260 Female Females

Related Publications

F W Bär, and J Meyer, and F Vermeer, and R Michels, and B Charbonnier, and K Haerten, and M Spiecker, and C Macaya, and M Hanssen, and M Heras, and J P Boland, and M C Morice, and F G Dunn, and R Uebis, and C Hamm, and O Ayzenberg, and G Strupp, and A J Withagen, and W Klein, and J Windeler, and G Hopkins, and H Barth, and M J von Fisenne
Effect of combined administration of saruplase and single-chain alteplase on coronary recanalization in acute myocardial infarction.
July 1989, The American journal of cardiology,
F W Bär, and J Meyer, and F Vermeer, and R Michels, and B Charbonnier, and K Haerten, and M Spiecker, and C Macaya, and M Hanssen, and M Heras, and J P Boland, and M C Morice, and F G Dunn, and R Uebis, and C Hamm, and O Ayzenberg, and G Strupp, and A J Withagen, and W Klein, and J Windeler, and G Hopkins, and H Barth, and M J von Fisenne
A comparison of reteplase with alteplase for acute myocardial infarction.
October 1997, The New England journal of medicine,
F W Bär, and J Meyer, and F Vermeer, and R Michels, and B Charbonnier, and K Haerten, and M Spiecker, and C Macaya, and M Hanssen, and M Heras, and J P Boland, and M C Morice, and F G Dunn, and R Uebis, and C Hamm, and O Ayzenberg, and G Strupp, and A J Withagen, and W Klein, and J Windeler, and G Hopkins, and H Barth, and M J von Fisenne
[Brazilian study with alteplase in acute myocardial infarction--EBRALT].
August 1995, Arquivos brasileiros de cardiologia,
F W Bär, and J Meyer, and F Vermeer, and R Michels, and B Charbonnier, and K Haerten, and M Spiecker, and C Macaya, and M Hanssen, and M Heras, and J P Boland, and M C Morice, and F G Dunn, and R Uebis, and C Hamm, and O Ayzenberg, and G Strupp, and A J Withagen, and W Klein, and J Windeler, and G Hopkins, and H Barth, and M J von Fisenne
Randomized, double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: the COMPASS Equivalence Trial. Comparison Trial of Saruplase and Streptokinase (COMASS) Investigators.
March 1998, Journal of the American College of Cardiology,
F W Bär, and J Meyer, and F Vermeer, and R Michels, and B Charbonnier, and K Haerten, and M Spiecker, and C Macaya, and M Hanssen, and M Heras, and J P Boland, and M C Morice, and F G Dunn, and R Uebis, and C Hamm, and O Ayzenberg, and G Strupp, and A J Withagen, and W Klein, and J Windeler, and G Hopkins, and H Barth, and M J von Fisenne
Comparison of double bolus urokinase versus front-loaded alteplase regimen for acute myocardial infarction. Thrombolysis in Myocardial Infarction in Korea (TIMIKO) study group.
September 1998, The American journal of cardiology,
F W Bär, and J Meyer, and F Vermeer, and R Michels, and B Charbonnier, and K Haerten, and M Spiecker, and C Macaya, and M Hanssen, and M Heras, and J P Boland, and M C Morice, and F G Dunn, and R Uebis, and C Hamm, and O Ayzenberg, and G Strupp, and A J Withagen, and W Klein, and J Windeler, and G Hopkins, and H Barth, and M J von Fisenne
Argatroban and alteplase in patients with acute myocardial infarction: the ARGAMI Study.
December 2000, Journal of thrombosis and thrombolysis,
F W Bär, and J Meyer, and F Vermeer, and R Michels, and B Charbonnier, and K Haerten, and M Spiecker, and C Macaya, and M Hanssen, and M Heras, and J P Boland, and M C Morice, and F G Dunn, and R Uebis, and C Hamm, and O Ayzenberg, and G Strupp, and A J Withagen, and W Klein, and J Windeler, and G Hopkins, and H Barth, and M J von Fisenne
Alteplase for acute myocardial infarction.
May 1988, Drug intelligence & clinical pharmacy,
F W Bär, and J Meyer, and F Vermeer, and R Michels, and B Charbonnier, and K Haerten, and M Spiecker, and C Macaya, and M Hanssen, and M Heras, and J P Boland, and M C Morice, and F G Dunn, and R Uebis, and C Hamm, and O Ayzenberg, and G Strupp, and A J Withagen, and W Klein, and J Windeler, and G Hopkins, and H Barth, and M J von Fisenne
Comparison of pharmacokinetics of lanoteplase and alteplase during acute myocardial infarction.
January 2002, Clinical pharmacokinetics,
F W Bär, and J Meyer, and F Vermeer, and R Michels, and B Charbonnier, and K Haerten, and M Spiecker, and C Macaya, and M Hanssen, and M Heras, and J P Boland, and M C Morice, and F G Dunn, and R Uebis, and C Hamm, and O Ayzenberg, and G Strupp, and A J Withagen, and W Klein, and J Windeler, and G Hopkins, and H Barth, and M J von Fisenne
Alteplase and anistreplase in acute myocardial infarction.
December 1989, Drug and therapeutics bulletin,
F W Bär, and J Meyer, and F Vermeer, and R Michels, and B Charbonnier, and K Haerten, and M Spiecker, and C Macaya, and M Hanssen, and M Heras, and J P Boland, and M C Morice, and F G Dunn, and R Uebis, and C Hamm, and O Ayzenberg, and G Strupp, and A J Withagen, and W Klein, and J Windeler, and G Hopkins, and H Barth, and M J von Fisenne
Tenecteplase and alteplase in acute myocardial infarction.
November 1999, Lancet (London, England),
Copied contents to your clipboard!